静脉-静脉体外膜氧合患者管理中的实践模式与伦理考量:一项国际调查
该研究为电子横断面情景调查,纳入39个国家539名有成人静脉-静脉体外膜氧合管理经验的主治医师。限制启动决策的影响因素包括高龄(46.9%)、其他器官衰竭(37.7%)和机械通气时间延长(35.1%);撤除决策的影响因素包括合并症(70.5%)、患者意愿(56.0%)和呼吸衰竭病因(37.7%)。多变量分析中,肺纤维化、卒中、代理人希望撤除、对患者或代理人意愿不知情、基线情景不启动及受访者宗教性等与撤除生命支持治疗 odds 增加相关;在无法违背患者或代理人意愿做出决定的环境中执业与撤除 odds 降低相关。90.5%受访者让其他医生参与决策,而涉及代理人、清醒患者和床旁护士的比例分别为53.2%、45.3%和29.5%。
要点
- 限制启动静脉-静脉体外膜氧合决策受高龄(46.9%)、其他器官衰竭(37.7%)和机械通气时间延长(35.1%)影响。
- 撤除决策受患者合并症(70.5%)、患者意愿(56.0%)和呼吸衰竭病因(37.7%)影响。
- 多变量分析中肺纤维化、卒中、代理人希望撤除、对患者或代理人意愿不知情、基线不启动及受访者宗教性与撤除生命支持治疗 odds 增加相关。
- 在无法违背患者或代理人意愿做出决定的环境中执业与撤除 odds 降低相关。
- 90.5%受访者让其他医生参与决策,涉及代理人、清醒患者和床旁护士的比例分别为53.2%、45.3%和29.5%。
适用人群与场景
- 39个国家539名主治级别医师,具有管理接受静脉-静脉体外膜氧合的成人患者的经验。
- 调查对象来自体外生命支持组织(Extracorporeal Life Support Organization)和国际体外膜氧合网络(International Extracorporeal Membrane Oxygenation Network)附属的体外膜氧合中心。
研究设计与关键结果
- 研究设计为电子横断面情景调查,共539名医师来自39个国家、六大洲完成调查。
- 限制静脉-静脉体外膜氧合启动决策的影响因素包括:患者年龄较大(46.9%)、其他器官衰竭(37.7%)、机械通气时间延长(35.1%)。
- 撤除静脉-静脉体外膜氧合决策的影响因素包括:患者合并症(70.5%)、患者意愿(56.0%)、呼吸衰竭病因(37.7%)。
- 多变量分析中,与撤除生命支持治疗 odds 增加相关的因素包括:肺纤维化、卒中、代理人希望撤除、在肺纤维化情况下对患者或代理人意愿不知情、基线情景中不启动体外膜氧合、受访者宗教性。
- 多变量分析中,与撤除 odds 降低相关的因素包括:在无法违背患者或代理人意愿做出决定的环境中执业。
- 90.5%的受访者让其他医生参与静脉-静脉体外膜氧合患者的治疗决策,而涉及代理人、清醒患者和床旁护士的比例分别为53.2%、45.3%和29.5%。
证据类型、等级与局限
- 证据类型:电子横断面情景调查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 调查显示,患者和医生层面因素与静脉-静脉体外膜氧合启动和撤除决策相关,包括患者预后及对患者或代理人意愿的了解程度。
- 受访者在管理接受静脉-静脉体外膜氧合的患者时,参与共同决策的比例较低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To characterize physicians' practices and attitudes toward the initiation, limitation, and withdrawal of venovenous extracorporeal membrane oxygenation for severe respiratory failure and evaluate factors associated with these attitudes.
DESIGN: Electronic, cross-sectional, scenario-based survey.
SETTING: Extracorporeal membrane oxygenation centers affiliated with the Extracorporeal Life Support Organization and the International Extracorporeal Membrane Oxygenation Network.
SUBJECTS: Attending-level physicians with experience managing adult patients receiving venovenous extracorporeal membrane oxygenation.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Five-hundred thirty-nine physicians in 39 countries across six continents completed the survey. Factors that influenced the decision to limit extracorporeal membrane oxygenation initiation included older patient age (46.9%), additional organ failures (37.7%), and prolonged mechanical ventilation (35.1%). Patient comorbidities (70.5%), patient's wishes (56.0%), and etiology of respiratory failure (37.7%) were factors that influenced the decision to withdraw extracorporeal membrane oxygenation. In multivariable analysis, factors associated with increased odds of withdrawing life-sustaining therapies included pulmonary fibrosis, stroke, surrogate's desire to withdraw, lack of knowledge regarding patient's or surrogate's wishes in the setting of fibrosis, not initiating extracorporeal membrane oxygenation in the baseline scenario, and respondent religiosity. Factors associated with decreased odds of withdrawal included practicing in an environment where it is not legally possible to make decisions against patient or surrogate wishes. Most respondents (90.5%) involved other physicians in treatment decisions for extracorporeal membrane oxygenation patients, whereas only 53.2%, 45.3%, and 29.5% of respondents involved surrogates, awake patients, or bedside nurses, respectively.
CONCLUSIONS: Patient and physician-level factors were associated with decision-making regarding extracorporeal membrane oxygenation initiation and withdrawal, including patient prognosis and knowledge of patient or surrogate wishes. Respondents reported low rates of engaging in shared decision-making when managing patients receiving extracorporeal membrane oxygenation.
参考来源
- Abrams D, Pham T, Burns KEA, et al. Practice Patterns and Ethical Considerations in the Management of Venovenous Extracorporeal Membrane Oxygenation Patients: An International Survey. Crit Care Med. 2019. PMID: 31356471. doi:10.1097/CCM.0000000000003910
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。